Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Targeted Drug Slows Thyroid Cancer
Aug. 16, 2012
In a small, placebo-controlled study, vandetanib (Caprelsa), a kinase inhibitor, delayed progression of the most common type of thyroid cancer, French researchers reported.
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing